Publications by authors named "Alma Magdalena Astorga-Ramos"
Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma.
Jeronimo Rafael Rodríguez-Cid Saul Campos-Gomez Vanessa García-Montes Manuel Magallanes-Maciel Rodrigo Rafael Flores-Mariñelarena Alma Magdalena Astorga-Ramos
JCO Glob Oncol
March 2020
Purpose: The LUME-Lung 1 study has brought consistent evidence of the effective use of nintedanib in lung adenocarcinoma as a second line of treatment; however, differences among ethnicities have been found in some studies.
Methods: This was a retrospective review among 21 medical centers of 150 patients with a confirmed diagnosis of lung adenocarcinoma, included in a compassionate use program of nintedanib from March 2014 to September 2015. The current study aimed to analyze the effectiveness of nintedanib in combination with docetaxel in the Mexican population, using progression-free survival rate and the best objective response to treatment by RECIST 1.
Article Synopsis
- * The consensus addresses the need for a multidisciplinary approach in managing lung cancer cases in Mexico, highlighting the evolution of treatment standards.
- * The paper reviews important aspects such as epidemiology, screening, diagnosis, staging, and various treatment options, including therapies for early and advanced stages, along with rehabilitation and palliative care.